Takeda Pharmaceutical (TAK) SEC Filings & 10K Form

$13.04
-0.04 (-0.31%)
(As of 04/26/2024 ET)

Recent Takeda Pharmaceutical SEC Filings

DateFilerForm TypeView
04/19/2024
5:12 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2024
5:02 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/10/2024
5:10 AM
Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13D/A
04/01/2024
5:15 AM
Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13D/A
03/27/2024
5:34 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/09/2024
5:03 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/06/2024
8:36 AM
BlackRock Inc. (Filed by)
Takeda Pharmaceutical (Subject)
Form SC 13G/A
02/05/2024
5:24 AM
Sumitomo Mitsui Trust Holdings, Inc. (Filed by)
Takeda Pharmaceutical (Subject)
Form SC 13G/A
02/02/2024
5:16 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/01/2024
5:18 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/01/2024
5:06 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/25/2024
5:13 AM
Phathom Pharmaceuticals, Inc. (Issuer)
Takeda Pharmaceutical (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/25/2024
5:11 AM
Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13D/A
01/19/2024
5:03 AM
Equillium, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13G
01/16/2024
5:01 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/14/2023
5:01 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/30/2023
5:01 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/13/2023
5:05 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/30/2023
5:02 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/26/2023
5:20 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/26/2023
5:22 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/18/2023
5:21 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/18/2023
5:20 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/02/2023
5:17 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/28/2023
5:17 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/11/2023
5:50 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/01/2023
5:10 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/27/2023
5:05 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/12/2023
5:07 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/10/2023
5:26 AM
Sequeira Ramona (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:33 AM
Bitetti Teresa Marie (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:35 AM
Takeda Pharmaceutical (Subject)
Wozniewski Thomas Otto Claus (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:16 AM
Kim Julie So-Young (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:20 AM
Duprey Lauren Rusckowski (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:22 AM
Pignagnoli Agosti Marcello (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:24 AM
Lugogo Mwana Pietrina (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:06 AM
Ricci Gabriele (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:09 AM
Plump Andrew Stewart (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:12 AM
Greco Gerard M (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:14 AM
Platford Giles Richard (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2023
5:18 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.
07/03/2023
5:02 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/28/2023
5:35 AM
Takeda Pharmaceutical (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
06/28/2023
5:00 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/28/2023
5:02 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/28/2023
5:07 AM
Takeda Pharmaceutical (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
06/23/2023
5:13 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/23/2023
5:10 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/09/2023
5:03 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/01/2023
5:02 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/30/2023
5:19 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/30/2023
5:20 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/30/2023
5:11 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/30/2023
5:14 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/26/2023
6:08 AM
Calithera Biosciences, Inc. (Issuer)
Takeda Pharmaceutical (Reporting)
Takeda Ventures, Inc. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/26/2023
6:08 AM
Calithera Biosciences, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13D/A
05/17/2023
5:02 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/15/2023
5:09 AM
Takeda Pharmaceutical (Filer)
Form SD
Specialized Disclosure Report  
05/11/2023
5:07 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/11/2023
5:10 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NYSE:TAK) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners